Co-Editor-in-Chief @JCardFail | Chief of the HF Section @DukeHealth | Trialist @DCRInews | Father of 3 | Better half = @JennaSkowronski
Durham, North Carolina
Joined June 2009
- Tweets4.2K
- Following8.7K
- Followers13.6K
- Likes7.6K
Robert Mentz, MD retweeted
🚨New Science Alert!
🫀DCD heart transplantation has expanded rapidly nationwide to more centers & higher-risk recipients. Yet graft failure, mortality & other early outcomes remained stable.
This UNOS analysis supports the robustness & scalability of DCD.
🧵👇
Robert Mentz, MD retweeted
🌍How do countries decide who gets a donor heart first? This research article analyzes heart allocation policies globally.
Across 29 countries, 93% of allocation systems use urgency tiers. But how urgency, MCS priority, & exceptions are defined varies widely.
🧵👇
Robert Mentz, MD retweeted
Tomorrow is the day!
Please send in your submissions by tomorrow! We cannot wait to see them!
@JCardFail @dranulala @slumberbell @Deoliveiragdc @robmentz
⏰Final Call
Submissions for JCF's Focus Issue: The New Frontier of Heart Function in Women close soon.
If your research advances women's cardiovascular health, now's the time to submit.
📅 Submissions close tomorrow, 9/15/26
bit.ly/4xQkPSR
#WomensHeartHealth
Robert Mentz, MD retweeted
🫀 Heart transplantation is entering a new era!
This State-of-the-Art review explores advances reshaping the field: individualized LVAD vs transplant decisions, DCD & HCV+ donors, and new organ preservation strategies expanding the donor pool.
🔗 bit.ly/45xVQXm
🧵👇
Robert Mentz, MD retweeted
New focus issue @JCardFail on 🫀transplantation is just 🔥🔥🔥 led by @EMDeFilippisMD @rcstarling @KiranKhush1 - it’s relevant, provocative, and just so easy to read.
Don’t miss it!! 👇🏽👇🏽👇🏽
onlinejcf.com/current
Robert Mentz, MD retweeted
What's next in heart transplantation? 🫀
Find out in the September Focus Issue on Innovations in Heart Transplantation.
Explore research and perspectives on new developments advancing heart transplantation care.
🔗 onlinejcf.com/current
#HeartTransplantation #Cardiology
Robert Mentz, MD retweeted
🚨New science alert!
PAWP or LVEDP ... which better predicts outcomes?
Using simultaneous invasive hemodynamics at rest & during exercise, this study found that PAWP better reflected hemodynamic abnormalities & predicted adverse HF outcomes. 🫀
🔗 bit.ly/4x64Z5K
Robert Mentz, MD retweeted
⏳ The deadline is approaching.
JCF is still accepting submissions for the Focus Issue: The New Frontier of Heart Function in Women.
If your research advances women's cardiovascular health, we encourage you to submit by 9/15/26.
bit.ly/4xQkPSR
Robert Mentz, MD retweeted
Now that sacubitril/valsartan is generic (<$13 a month)
PARAGON-HF: PEP rate ratio, 0.87; 95% CI 0.75 to 1.01; P=0.059
PARAGLIDE-HF + PARAGON-HF total events RR 0.86; 95% CI 0.75–0.98; P=0.027
S/V vs imputed placebo RR 0.71 95% CI 0.54–0.93; P=0.013
Class 2b ➡️ Class 1?
Robert Mentz, MD retweeted
🧬Precision medicine begins with a diagnosis.
In the largest real-world study to date, only 1.05% of patients with cardiomyopathy underwent genetic testing and just 7% received genetic counseling. Implementation — not evidence — remains the challenge.
🔗 bit.ly/4qpMbvF
Robert Mentz, MD retweeted
So proud of Kristin Corey, an incredible pulmonary fellow @DukeMedSchool who led this great work! A protein score that predicts MACE and is modifiable by GLP-1 RA @LiJenniferS @kcooney1234 @pamelasdouglas @robmentz @texhern @RobGersztenMD
This proteomic score outperforms widely used clinical risk models for major adverse cardiovascular events among individuals with diabetes: doi.org/10.1172/jci.insight.…
Svati H. Shah @SvatiShah & team @DukeMedSchool report on blood proteins that help predict heart disease risk in type 2 diabetes and are modified by GLP-1 therapy, improving risk assessment beyond traditional clinical factors.
@the_asci @texhern
#HeartDisease #Diabetes
Robert Mentz, MD retweeted
🫀🧬 Is suPAR more than a biomarker?
In SOLOIST-WHF, higher baseline suPAR predicted worse HF outcomes, but sotagliflozin reduced events regardless of suPAR and did not lower suPAR levels — pointing to residual inflammatory risk.
🔗 bit.ly/4qjyrT0
Robert Mentz, MD retweeted
🫀Does transplant center volume influence DCD heart transplant outcomes?
This UNOS analysis found similar perioperative outcomes and short-term survival at high & low-volume centers, supporting the growing robustness & reproducibility of DCD transplantation.
🧵👇
Robert Mentz, MD retweeted
❤️ Calling clinicians & 🏨s
Join #AHA GWTG-HF to raise the bar on HF care 📈
✅ Evidence-based meds 💊
✅ Follow-up appointments locked in 📅
✅ Quadruple therapy 🎯
✅ Better outcomes for patients ❤️🩹
Turn guidelines into ⤴️ care and outcomes
👉 Heart.org/quality
Robert Mentz, MD retweeted
🫀Is predicted heart mass still the best way to size-match donor hearts?
This Perspective questions PHM in the modern era, highlighting its limitations in obesity & calling for next-generation metrics that better reflect body composition & cardiac size.
bit.ly/45xRZtm
Robert Mentz, MD retweeted
Powerful piece from @SunnyVMD on losing his dad. Impactful message on the grieving clinician. Grateful for your vulnerability. @JCardFail @dranulala @DrMarthaGulati @AndrewJSauer
The Case I Could Not Solve - onlinejcf.com/article/S1071-…
Powerful piece from @SunnyVMD on losing his dad. Impactful message on the grieving clinician. Grateful for your vulnerability. @JCardFail @dranulala @DrMarthaGulati @AndrewJSauer
The Case I Could Not Solve - onlinejcf.com/article/S1071-…
ICYMI: The May episode of #HFBeat featured the May special focus issue of @JCardFail on infiltrative & inflammatory cardiomyopathies.
🎧 In this clip, Mathew Maurer, MD explains how non-biopsy diagnosis and emerging therapies transformed the field of amyloidosis and why earlier diagnosis is critical for improving outcomes. “The therapies really did change the landscape dramatically.”
Listen here: hfsa.org/heart-failure-beat-…
@MHBeasleyMD @priyaumapathi @dranulala @robmentz
Robert Mentz, MD retweeted
🫀Out-of-sequence heart transplantation remains uncommon. But it's growing.
This study found OOS allocation increased from 1.4% to 3.1%, was concentrated in a small number of OPOs & centers, & achieved similar 1-year survival to standard allocation.
🔗 bit.ly/4qhMFDS
Robert Mentz, MD retweeted
Congratulations to #HFC member Dr. Nosheen Reza on receiving the 2026 HFSA Rising Star Award! 🏆
So well deserved! @JCFINT @JasonKatzMD @noshreza @robmentz
Congratulations to the 2026 HFSA Award recipients! 🏆
We're proud to recognize the individuals and teams whose leadership, innovation, research, mentorship & service are advancing heart failure care.
Meet the honorees being recognized at #HFSA2026: hfsa.org/members-and-leaders…
